Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
RANI Stock Forecast 2026-2027
$0.83
Current Price
$114.04M
Market Cap
Buy 4
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to RANI Price Targets
+1,226.1%
To High Target of $11.00
+743.9%
To Median Target of $7.00
+502.8%
To Low Target of $5.00
RANI Price Momentum
-12.6%
1 Week Change
-10.8%
1 Month Change
+48.2%
1 Year Change
-38.5%
Year-to-Date Change
-78.6%
From 52W High of $3.87
+114.3%
From 52W Low of $0.39
📊 TOP ANALYST CALLS
Did RANI Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Rani Therapeutics is one of their latest high-conviction picks.
Latest RANI Stock Price Targets & Analyst Predictions
Based on our analysis of 3 Wall Street analysts, RANI has a bullish consensus with a median price target of $7.00 (ranging from $5.00 to $11.00). The overall analyst rating is Strong Buy (9.5/10). Currently trading at $0.83, the median forecast implies a 743.9% upside. This outlook is supported by 4 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Brandon Folkes at HC Wainwright & Co., projecting a 1,226.1% upside. Conversely, the most conservative target is provided by Edward Nash at Canaccord Genuity, suggesting a 502.8% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
RANI Analyst Ratings
4
Buy
0
Hold
0
Sell
RANI Price Target Range
Low
$5.00
Average
$7.00
High
$11.00
Current: $0.83
Latest RANI Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for RANI.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 20, 2026 | Canaccord Genuity | Edward Nash | Buy | Maintains | $5.00 |
| Apr 1, 2026 | Canaccord Genuity | Buy | Maintains | $N/A | |
| Mar 27, 2026 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Jan 9, 2026 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Oct 21, 2025 | HC Wainwright & Co. | Brandon Folkes | Buy | Assumes | $11.00 |
| Oct 20, 2025 | Maxim Group | Buy | Maintains | $N/A | |
| May 16, 2025 | Oppenheimer | Outperform | Maintains | $N/A | |
| Apr 3, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Feb 26, 2025 | Canaccord Genuity | Buy | Maintains | $N/A | |
| Feb 7, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Nov 19, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Oct 18, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Aug 16, 2024 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Aug 2, 2024 | Oppenheimer | Outperform | Initiates | $N/A | |
| Jun 25, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Jun 14, 2024 | Maxim Group | Buy | Initiates | $N/A | |
| Jun 13, 2024 | Rodman & Renshaw | Buy | Initiates | $N/A | |
| May 9, 2024 | BTIG | Buy | Maintains | $N/A | |
| May 7, 2024 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Mar 27, 2024 | Canaccord Genuity | Buy | Maintains | $N/A |
Rani Therapeutics Holdings Inc. (RANI) Competitors
The following stocks are similar to Rani Therapeutics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Rani Therapeutics Holdings Inc. (RANI) Financial Data
Rani Therapeutics Holdings Inc. has a market capitalization of $114.04M with a P/E ratio of -1.8x. The company generates $3.17M in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is +893.0% quarter-over-quarter, while maintaining an operating margin of -488.2% and return on equity of -240.0%.
Valuation Metrics
Market Cap
$114.04M
Enterprise Value
$50.55M
P/E Ratio
-1.8x
PEG Ratio
0.0x
Price/Sales
36.0x
Growth & Margins
Revenue Growth (YoY)
+893.0%
Gross Margin
N/A
Operating Margin
-488.2%
Net Margin
0.0%
EPS Growth
+893.0%
Financial Health
Cash/Price Ratio
+52.3%
Current Ratio
3.4x
Debt/Equity
11.1x
ROE
-240.0%
ROA
-57.0%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Rani Therapeutics Holdings Inc. (RANI) Business Model
About Rani Therapeutics Holdings Inc.
What They Do
Innovative biopharmaceutical drug delivery solutions.
Business Model
The company develops the RaniPill capsule to enable the oral delivery of biologic drugs, traditionally administered via injections. By addressing the challenges of oral administration, Rani Therapeutics aims to enhance patient compliance and expand market access for treatments of chronic diseases, generating revenue through partnerships and potential licensing agreements with pharmaceutical manufacturers.
Additional Information
Rani Therapeutics is positioned as a disruptive force in the healthcare sector, focusing on solutions for conditions like diabetes and autoimmune disorders. Its innovative technology has the potential to significantly impact the biopharmaceutical landscape, making it an attractive investment opportunity for those interested in health tech advancements.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
69
CEO
Mr. Talat Imran
Country
United States
IPO Year
2018
Website
www.ranitherapeutics.comRani Therapeutics Holdings Inc. (RANI) Latest News & Analysis
Latest News
Quick Summary
Rani Therapeutics has secured a securities purchase agreement to sell 12.48 million Class A shares at $1.07 each and pre-funded warrants for 6.21 million shares at $1.0699, led by a sovereign wealth fund.
Why It Matters
Rani Therapeutics' capital raise indicates strong investor confidence, which can bolster stock liquidity and support ongoing clinical development, potentially enhancing future valuation and growth prospects.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
The Phase 1 study of RT-114, using RaniPill® for obesity treatment, is progressing in collaboration with ProGen.
Why It Matters
Progress in the Phase 1 study of RT-114 indicates potential for a new obesity treatment, which could enhance market opportunities and value for involved companies, impacting stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Rani Therapeutics to Participate in the H.C. Wainwright Annual BioConnect Investor Conference
25 days ago
Quick Summary
Rani Therapeutics Holdings, Inc. (Nasdaq: RANI) announced its management will participate in an upcoming event, focusing on oral delivery of biologics and drugs.
Why It Matters
Rani Therapeutics' participation in the H.C. conference signals potential visibility and investor interest in its drug delivery innovations, impacting stock performance and market perception.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Rani Therapeutics appointed Dr. Sara Kenkare-Mitra as a Strategic Advisor. She has 30 years of experience in biologics and drug development, with a strong record in global approvals and launches.
Why It Matters
The appointment of Dr. Kenkare-Mitra enhances Rani Therapeutics' expertise in drug development, potentially accelerating product approvals and increasing its market competitiveness.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Rani Therapeutics Holdings, Inc. (RANI) held its Q4 2025 earnings call, discussing financial performance and future outlook. For detailed insights, refer to the full transcript.
Why It Matters
Rani Therapeutics' Q4 2025 earnings reveal financial performance and growth strategies, impacting investors' assessments of the company's future profitability and stock value.
Source: Seeking Alpha
Market Sentiment:
Neutral
Rani Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results; Provides Corporate Update
2 months ago
Quick Summary
The company announced a collaboration worth up to $1.085 billion with Chugai Pharmaceutical and a $60.3 million oversubscribed private placement. Preclinical data for oral therapies was also released, and a Phase 1 study for RT-114 began.
Why It Matters
The collaboration with Chugai and successful funding indicate strong investor confidence. Positive preclinical results and Phase 1 initiation boost potential for future revenue, enhancing stock appeal.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About RANI Stock
What is Rani Therapeutics Holdings Inc.'s (RANI) stock forecast for 2026?
Based on our analysis of 3 Wall Street analysts, Rani Therapeutics Holdings Inc. (RANI) has a median price target of $7.00. The highest price target is $11.00 and the lowest is $5.00.
Is RANI stock a good investment in 2026?
According to current analyst ratings, RANI has 4 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.83. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for RANI stock?
Wall Street analysts predict RANI stock could reach $7.00 in the next 12 months. This represents a 743.9% increase from the current price of $0.83. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Rani Therapeutics Holdings Inc.'s business model?
The company develops the RaniPill capsule to enable the oral delivery of biologic drugs, traditionally administered via injections. By addressing the challenges of oral administration, Rani Therapeutics aims to enhance patient compliance and expand market access for treatments of chronic diseases, generating revenue through partnerships and potential licensing agreements with pharmaceutical manufacturers.
What is the highest forecasted price for RANI Rani Therapeutics Holdings Inc.?
The highest price target for RANI is $11.00 from Brandon Folkes at HC Wainwright & Co., which represents a 1,226.1% increase from the current price of $0.83.
What is the lowest forecasted price for RANI Rani Therapeutics Holdings Inc.?
The lowest price target for RANI is $5.00 from Edward Nash at Canaccord Genuity, which represents a 502.8% increase from the current price of $0.83.
What is the overall RANI consensus from analysts for Rani Therapeutics Holdings Inc.?
The overall analyst consensus for RANI is bullish. Out of 3 Wall Street analysts, 4 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $7.00.
How accurate are RANI stock price projections?
Stock price projections, including those for Rani Therapeutics Holdings Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 7, 2026 1:33 AM UTC